Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Projected to Reach US$ 45.51 Billion by 2034: Fact.MR Study
December 10, 2023 17:00 ET | FACT.MR
Rockville , Dec. 10, 2023 (GLOBE NEWSWIRE) -- Expanding at 6.2% CAGR from 2024 to 2034, the global attention deficit hyperactivity disorder (ADHD) therapeutics market is estimated to reach a...
RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.
March 04, 2020 09:00 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of ampakines for a variety...